Co-Diagnostics, Inc. (MUN:C970)
9.96
-0.54 (-5.14%)
At close: Nov 26, 2025
Co-Diagnostics Revenue
Co-Diagnostics had revenue of $145.38K USD in the quarter ending September 30, 2025, a decrease of -77.32%. This brings the company's revenue in the last twelve months to $507.89K, down -93.06% year-over-year. In the year 2024, Co-Diagnostics had annual revenue of $3.92M, down -42.53%.
Revenue (ttm)
$507.89K
Revenue Growth
-93.06%
P/S Ratio
24.62
Revenue / Employee
$3.85K
Employees
132
Market Cap
10.66M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.92M | -2.90M | -42.53% |
| Dec 31, 2023 | 6.81M | -27.41M | -80.09% |
| Dec 31, 2022 | 34.22M | -63.67M | -65.04% |
| Dec 31, 2021 | 97.89M | 23.33M | 31.30% |
| Dec 31, 2020 | 74.55M | 74.34M | 34,579.90% |
| Dec 31, 2019 | 214.97K | 175.06K | 438.63% |
| Dec 31, 2018 | 39.91K | 32.25K | 420.90% |
| Dec 31, 2017 | 7.66K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 10.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Co-Diagnostics News
- 9 days ago - Co-Diagnostics Announces Reverse Stock Split - PRNewsWire
- 10 days ago - Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies - PRNewsWire
- 21 days ago - Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India - PRNewsWire
- 22 days ago - Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation - PRNewsWire
- 4 weeks ago - Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025 - PRNewsWire
- 4 weeks ago - Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - PRNewsWire
- 7 weeks ago - Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health - PRNewsWire
- 7 weeks ago - Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA - PRNewsWire